Inflammatory bowel diseases (Crohn’s disease and Ulcerative colitis).
Interplay of inflammatory bowel diseases and “functional” or irritable bowel syndrome.
Recurrent Clostridium difficile infections requiring “fecal transplant”.
Marcus has received funding from the Crohn’s and Colitis Foundation of America (CCFA) to investigate the role of the microbiota and innate sensors in the development of colitis-associated colon cancer. His work was cited more than 1200 times by other scientists, and his H index (measure for academic productivity) is 20.
Marcus will pursue a career in academics and his lab (starting 2014) will mainly work on a better understanding of how the microbiota affects intestinal stem cell regeneration and differentiation in inflammatory bowel diseases. His goal is to find new innovative treatment approaches for a subset of patients with IBD.
Education and Training
|MD||University of Regensburg (Germany)||Medicine|
|University of Regensburg (Germany)||Experimental Internal Medicine|
|Residency/Fellowship||University of Regensburg (German)||Internal Medicine|
|Residency (USA)||University of North Carolina at Chapel Hill||Internal Medicine|
|Fellowship (USA)||University of North Carolina at Chapel Hill||Gastroenterology|